MA37794B1 - Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le cadre du traitement de pathologies vasculaires oculaires - Google Patents

Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le cadre du traitement de pathologies vasculaires oculaires

Info

Publication number
MA37794B1
MA37794B1 MA37794A MA37794A MA37794B1 MA 37794 B1 MA37794 B1 MA 37794B1 MA 37794 A MA37794 A MA 37794A MA 37794 A MA37794 A MA 37794A MA 37794 B1 MA37794 B1 MA 37794B1
Authority
MA
Morocco
Prior art keywords
vegf
ang
bispecific antibodies
treatment
ocular vascular
Prior art date
Application number
MA37794A
Other languages
English (en)
Other versions
MA37794A1 (fr
Inventor
Harald Duerr
Frank Herting
Christian Klein
Joerg Thomas Regula
Matthias Rueth
Kay-Gunnar Stubenrauch
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48783248&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37794(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of MA37794A1 publication Critical patent/MA37794A1/fr
Publication of MA37794B1 publication Critical patent/MA37794B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La présente invention concerne des anticorps bispécifiques dirigés contre le facteur de croissance de l'endothélium vasculaire humain (vegf/vegf-a) et contre l'angiopoïétine 2 humaine (ang-2) des sous-classes d'igg1 ou d'igg4 humaines porteuses des mutations i253a, h310a et h435a, leurs procédés de production, des compositions pharmaceutiques contenant lesdits anticorps et leurs utilisations.
MA37794A 2012-07-13 2013-07-11 Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le cadre du traitement de pathologies vasculaires oculaires MA37794B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12176299 2012-07-13
PCT/EP2013/064672 WO2014009465A1 (fr) 2012-07-13 2013-07-11 Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le cadre du traitement de pathologies vasculaires oculaires

Publications (2)

Publication Number Publication Date
MA37794A1 MA37794A1 (fr) 2016-03-31
MA37794B1 true MA37794B1 (fr) 2017-07-31

Family

ID=48783248

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37794A MA37794B1 (fr) 2012-07-13 2013-07-11 Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le cadre du traitement de pathologies vasculaires oculaires

Country Status (40)

Country Link
US (4) US9695233B2 (fr)
EP (2) EP2872534B1 (fr)
JP (5) JP6154900B2 (fr)
KR (1) KR101774121B1 (fr)
CN (1) CN104428315B (fr)
AR (2) AR092027A1 (fr)
AU (1) AU2013288641B2 (fr)
CA (1) CA2874554C (fr)
CL (2) CL2015000061A1 (fr)
CO (1) CO7151542A2 (fr)
CR (1) CR20140542A (fr)
CY (1) CY1124681T1 (fr)
DK (2) DK3495387T3 (fr)
EA (1) EA032192B1 (fr)
ES (2) ES2690312T3 (fr)
FI (1) FIC20230011I1 (fr)
FR (1) FR23C1010I2 (fr)
HK (1) HK1206365A1 (fr)
HR (2) HRP20211641T1 (fr)
HU (2) HUE056217T2 (fr)
IL (1) IL236292B (fr)
IN (1) IN2014DN11157A (fr)
LT (3) LT2872534T (fr)
MA (1) MA37794B1 (fr)
MX (1) MX361337B (fr)
MY (1) MY183712A (fr)
NL (1) NL301218I2 (fr)
NO (1) NO2023009I1 (fr)
NZ (1) NZ702201A (fr)
PE (1) PE20150361A1 (fr)
PH (1) PH12014502713B1 (fr)
PL (2) PL3495387T3 (fr)
PT (1) PT2872534T (fr)
RS (2) RS57704B1 (fr)
SG (1) SG11201408538PA (fr)
SI (2) SI3495387T1 (fr)
TW (1) TWI506036B (fr)
UA (1) UA120029C2 (fr)
WO (1) WO2014009465A1 (fr)
ZA (1) ZA201408969B (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ571300A (en) 2006-04-07 2011-12-22 Warner Chilcott Co Llc Antibodies that bind human protein tyrosine phosphatase beta (HPTPBeta) and uses thereof
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
TR201818814T4 (tr) 2009-10-16 2019-01-21 Oncomed Pharm Inc Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı.
PT2758073T (pt) 2011-09-23 2019-02-01 Oncomed Pharm Inc Agentes de ligação a vegf/dll4 e utilizações dos mesmos
JP6152120B2 (ja) 2012-02-15 2017-06-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｆｃ受容体に基づくアフィニティークロマトグラフィー
PL3495387T3 (pl) 2012-07-13 2022-01-10 Roche Glycart Ag Dwuswoiste przeciwciała anty-VEGF/anty-ANG-2 i ich zastosowanie w leczeniu chorób naczyniowych oka
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
CN104903349B (zh) 2012-11-08 2018-10-19 十一生物治疗股份有限公司 Il-6拮抗剂及其应用
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
PL2992012T3 (pl) 2013-04-29 2019-12-31 F. Hoffmann-La Roche Ag Zmodyfikowane ludzkie przeciwciała wiążące FcRn i sposoby ich zastosowania
MX2016006743A (es) * 2013-12-13 2016-08-12 Hoffmann La Roche Ensayo de puente a base de resonancia de plasmon superficial para determinar la actividad biologica de moleculas multiespecificas multivalentes.
MX2016008782A (es) 2014-01-15 2016-09-08 Hoffmann La Roche Variantes de region fc con union mejorada de la proteina a.
US9994560B2 (en) 2014-03-14 2018-06-12 Aerpio Therapeutics, Inc. HPTP-β inhibitors
EP3125937A4 (fr) * 2014-04-04 2017-11-01 Oncomed Pharmaceuticals, Inc. Traitement du cancer gastrique
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN106536559B (zh) * 2014-07-17 2021-04-27 诺和诺德股份有限公司 定点诱变trem-1抗体以降低黏度
DK3212233T3 (da) 2014-10-31 2020-07-27 Oncomed Pharm Inc Kombinationsterapi til behandling af sygdom
CN107074966A (zh) 2014-11-06 2017-08-18 豪夫迈·罗氏有限公司 具有改变的FCRN‑和蛋白A‑结合性质的Fc区变体
JP6707090B2 (ja) 2014-11-06 2020-06-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＦｃＲｎ結合が変更されたＦｃ領域変種および使用方法
EA035199B1 (ru) 2014-11-07 2020-05-14 Сесен Байо, Инк. Улучшенные антитела против il-6
CN107148429B (zh) 2014-11-10 2021-12-03 豪夫迈·罗氏有限公司 抗-pdgf-b抗体和使用方法
SG11201703428SA (en) * 2014-11-10 2017-05-30 Hoffmann La Roche Bispecific antibodies and methods of use in ophthalmology
KR20170081253A (ko) 2014-11-10 2017-07-11 에프. 호프만-라 로슈 아게 항-il-1베타 항체 및 이의 사용 방법
CA2963606A1 (fr) * 2014-11-10 2016-05-19 F.Hoffmann-La Roche Ag Anticorps anti-ang2 et methodes d'utilisation correspondantes
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
AR103477A1 (es) * 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
PL3328886T3 (pl) * 2015-07-29 2021-02-08 Allergan, Inc. Przeciwciała ang-2 o wyłącznie ciężkim łańcuchu
MX2018001566A (es) 2015-08-07 2019-04-25 Imaginab Inc Construcciones de union a antigeno para moleculas diana.
EP3350217A4 (fr) * 2015-09-14 2019-09-04 Galaxy Biotech LLC Anticorps monoclonaux hautement puissants dirigés contre des facteurs angiogéniques
EP3353204B1 (fr) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Anticorps anti-vegf/dll4 bi-spécifique pour le traitement du cancer de l'ovaire résistant au platine
SG10201912000WA (en) 2015-09-23 2020-02-27 Aerpio Therapeutics Inc Methods of treating intraocular pressure with activators of tie-2
CN108137681A (zh) 2015-09-23 2018-06-08 豪夫迈·罗氏有限公司 抗-vegf抗体的优化的变体
MA43018B1 (fr) * 2015-10-02 2021-11-30 Hoffmann La Roche Anticorps anti-pd1 et procédés d'utilisation
CN108137699B (zh) 2015-10-02 2022-05-27 豪夫迈·罗氏有限公司 对pd1和tim3特异性的双特异性抗体
KR20180069065A (ko) * 2015-10-29 2018-06-22 에프. 호프만-라 로슈 아게 항-변이체 fc-부위 항체 및 사용 방법
EP3383921A4 (fr) * 2015-11-30 2019-04-17 Pieris Australia Pty Ltd. Nouveaux polypeptides de fusion anti-angiogéniques
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2017113181A1 (fr) * 2015-12-30 2017-07-06 深圳先进技术研究院 Anticorps bispécifique hybride d'igg contre le tnfa et l'il-17a
US11708390B2 (en) 2016-05-11 2023-07-25 Cytiva Bioprocess R&D Ab Method of storing a separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10513537B2 (en) 2016-05-11 2019-12-24 Ge Healthcare Bioprocess R&D Ab Separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US11753438B2 (en) 2016-05-11 2023-09-12 Cytiva Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
MX2018015173A (es) * 2016-06-17 2019-07-04 Genentech Inc Purificacion de anticuerpos multiespecificos.
WO2018007314A1 (fr) * 2016-07-04 2018-01-11 F. Hoffmann-La Roche Ag Nouveau format d'anticorps
KR20190031246A (ko) 2016-07-20 2019-03-25 에르피오 세러퓨틱스 인코포레이티드 VE-PTP (HPTP-β)를 표적으로 하는 인간화된 단클론성 항체
US11504431B2 (en) 2016-07-20 2022-11-22 Emory University Formulations for the suprachoroidal space of an eye and methods
MA46036A (fr) * 2016-08-23 2019-07-03 Medimmune Ltd Anticorps anti-vegf-a et anti-ang2 et leurs utilisations
EP3519439A2 (fr) * 2016-09-29 2019-08-07 Amgen Inc. Protéines de liaison à l'antigène à viscosité faible et leurs procédés de préparation
JP6785372B2 (ja) * 2016-09-30 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性分子の機能分析のためのｓｐｒに基づく二重結合アッセイ
CN108299557A (zh) * 2017-01-13 2018-07-20 杭州翰思生物医药有限公司 提高IgG类抗体对FcRn的结合亲和力并延长其血清半衰期的方法
WO2018147960A1 (fr) 2017-02-08 2018-08-16 Imaginab, Inc. Séquences d'extension pour dianticorps
WO2018175752A1 (fr) 2017-03-22 2018-09-27 Genentech, Inc. Compositions d'anticorps optimisées pour le traitement de troubles oculaires
WO2018175788A1 (fr) 2017-03-22 2018-09-27 Genentech, Inc. Compositions de promédicament d'hydrogel d'acide hyaluronique réticulé et procédés
DK3606946T3 (da) 2017-04-03 2022-10-24 Hoffmann La Roche Immunkonjugater af et anti-PD-1-antistof med et muteret IL-2 eller med IL-15
TWI747215B (zh) 2017-04-05 2021-11-21 瑞士商赫孚孟拉羅股份公司 特異性結合至pd1至lag3的雙特異性抗體
EP3626745A4 (fr) * 2017-09-01 2021-03-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anticorps bispécifique recombinant
CN111491951A (zh) * 2017-12-22 2020-08-04 豪夫迈·罗氏有限公司 通过疏水相互作用色谱法耗尽轻链错配的抗体变体
CN110283248B (zh) * 2018-01-05 2020-07-28 百奥泰生物制药股份有限公司 一种长效低毒的重组抗vegf人源化单克隆抗体及其生产方法
MX2020007527A (es) * 2018-02-06 2020-09-09 Hoffmann La Roche Tratamiento de enfermedades oftalmologicas.
CN110305210B (zh) * 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
EP3560945A1 (fr) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Procédés de purification de polypeptides utilisant des polysorbates
JP7249060B2 (ja) * 2018-08-17 2023-03-30 トリカン・バイオテクノロジー・カンパニー・リミテッド 抗血管新生融合タンパク質およびその使用
CN113164597A (zh) 2018-09-24 2021-07-23 爱尔皮奥制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
PE20211865A1 (es) * 2018-10-29 2021-09-21 Hoffmann La Roche Formulacion de anticuerpos
AU2019406712A1 (en) 2018-12-21 2021-06-17 F. Hoffmann-La Roche Ag Antibody that binds to VEGF and IL-1beta and methods of use
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
CN114269341A (zh) 2019-04-29 2022-04-01 视点制药公司 靶向施莱姆管的Tie-2激活剂
EP3986924A1 (fr) 2019-06-19 2022-04-27 F. Hoffmann-La Roche AG Procédé de génération d'une cellule exprimant un anticorps multivalent, multispécifique par intégration ciblée de multiples cassettes d'expression dans une organisation définie
MX2021015538A (es) 2019-06-19 2022-02-10 Hoffmann La Roche Metodo para la generacion de una celula que expresa un anticuerpo biespecifico bivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida.
AU2020326243A1 (en) * 2019-08-06 2022-02-17 F. Hoffmann-La Roche Ag Personalized treatment of ophthalmologic diseases
WO2021072265A1 (fr) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Procédés de traitement d'un trouble oculaire
JP2023514727A (ja) 2020-02-21 2023-04-07 シルバーバック セラピューティックス インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
BR112022018254A2 (pt) 2020-03-13 2022-10-25 Genentech Inc Anticorpos isolados, ácido nucleico isolado, vetor ou conjunto de vetores, célula hospedeira, métodos para produzir um anticorpo, para tratar um distúrbio e para tratar ag em um paciente, composição e uso de um anticorpo
CN115867649A (zh) 2020-03-24 2023-03-28 基因泰克公司 Tie2结合剂及其使用方法
WO2021198034A1 (fr) 2020-03-30 2021-10-07 F. Hoffmann-La Roche Ag Anticorps se liant à vegf et pdgf-b et méthodes d'utilisation
WO2022006327A1 (fr) 2020-07-01 2022-01-06 Silverback Therapeutics, Inc. Conjugués d'anticorps anti-asgr1 et leurs utilisations
WO2022008699A1 (fr) 2020-07-09 2022-01-13 F. Hoffmann-La Roche Ag Compositions concentrées de protéines, leur préparation et l'utilisation associée
EP4208201A1 (fr) 2020-09-04 2023-07-12 F. Hoffmann-La Roche AG Anticorps se liant à vegf-a et à ang2 et méthodes d'utilisation
TW202221027A (zh) * 2020-09-17 2022-06-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｖｅｇｆ和ａｎｇ－２的雙特異性抗原結合分子
IL302089A (en) 2020-10-15 2023-06-01 Hoffmann La Roche Non-covalent protein-hyaluronan conjugates for long-term ocular delivery
WO2022226539A1 (fr) * 2021-04-23 2022-10-27 Immunome, Inc. Méthodes d'administration d'anticorps contre la protéine de spicule du sars-cov-2
CN117500828A (zh) 2021-06-04 2024-02-02 信达生物制药(苏州)有限公司 结合VEGF和Ang2的双特异性结合分子以及其用途
WO2023028004A1 (fr) * 2021-08-23 2023-03-02 Avirmax, Inc. Compositions et méthodes d'expression transgénique
CN116265487A (zh) * 2021-12-16 2023-06-20 三优生物医药(上海)有限公司 抗ang2-vegf双特异性抗体及其用途
WO2024065268A1 (fr) * 2022-09-28 2024-04-04 科兴生物制药股份有限公司 Anticorps ou fragment de liaison à l'antigène capable d'identifier ang-2, et anticorps bispécifique pour identifier simultanément vegf et ang-2

Family Cites Families (318)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4490473A (en) 1983-03-28 1984-12-25 Panab Labeled antibodies and methods
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4752601A (en) 1983-08-12 1988-06-21 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin FC receptors
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5985599A (en) 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
WO1989006692A1 (fr) 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
US5576184A (en) 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
DE68928427T2 (de) 1988-09-15 1998-06-04 Univ Columbia Antikörper mit modifiziertem Kohlenhydratgehalt und Verfahren zur Herstellung und Verwendung
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB8916400D0 (en) 1989-07-18 1989-09-06 Dynal As Modified igg3
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (fr) 1989-10-25 2006-02-07 Ravi J. Chari Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5364930A (en) 1990-10-16 1994-11-15 Northwestern University Synthetic C1q peptide fragments
US5419904A (en) 1990-11-05 1995-05-30 The Regents Of The University Of California Human B-lymphoblastoid cell line secreting anti-ganglioside antibody
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9105245D0 (en) 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
WO1993006217A1 (fr) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION DANS L'E. COLI DE FRAGMENTS D'ANTICORPS POSSEDANT AU MOINS UNE CYSTEINE PRESENTE SOUS FORME D'UN THIOL LIBRE, ET LEUR UTILISATION DANS LA PRODUCTION D'ANTICORPS BIFONCTIONNELS F(ab')¿2?
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
DE4137512A1 (de) 1991-11-15 1993-05-19 Henkel Kgaa Heisssiegelbeschichtung auf dispersionsbasis
WO1993010260A1 (fr) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Utilisation de la neuraminidase extracellulaire pour lutter contre la degradation d'oligosaccharides de la glycoproteine
EP1997894B1 (fr) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Protéine de liaison biosynthétique pour un marqueur du cancer
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
WO1993022332A2 (fr) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Production recombinante de domaines semblables a l'immunoglobuline dans des cellules procaryotes
AU5138993A (en) 1992-09-28 1994-04-26 Midwest Research Institute Fermentation of cellulose and hemicellulose in corn fiber and distillers dried grains with solubles to ethanol
ES2173873T5 (es) 1992-10-28 2007-03-01 Genentech, Inc. Utilizacion de anticuerpos anti-vegf para el tratamiento del cancer.
WO1994011026A2 (fr) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Application therapeutique d'anticorps chimeriques et radio-marques contre l'antigene a differentiation restreinte des lymphocytes b humains pour le traitement du lymphome des cellules b
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5412468A (en) 1993-03-09 1995-05-02 The Perkin-Elmer Corporation Grouping of spectral bands for data acquisition in a spectrophotometer
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
CA2163345A1 (fr) 1993-06-16 1994-12-22 Susan Adrienne Morgan Anticorps
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
WO1995009917A1 (fr) 1993-10-07 1995-04-13 The Regents Of The University Of California Anticorps bispecifiques et tetravalents, obtenus par genie genetique
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
AU690474B2 (en) 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
DE19533718A1 (de) 1995-09-12 1997-03-13 Basf Ag Verfahren zur Hydrierung von aromatischen Verbindungen, in denen mindestens eine Aminogruppe an einen aromatischen Kern gebunden ist
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1997043316A1 (fr) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Molecules physiologiquement actives a demi-vies prolongees et methode d'utilisation de ces dernieres
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
JP2000516452A (ja) 1996-07-16 2000-12-12 プリュックテュン，アンドレアス 可溶性が増大した免疫グロブリンスーパーファミリードメインおよびフラグメント
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
ATE356212T1 (de) 1997-01-31 2007-03-15 Genentech Inc O-fukosyltransferase
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6323321B1 (en) 1997-03-05 2001-11-27 Eberhard-Karls-Universitat Tubingen Universitatsklinikum Antibody 97A6
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
CN104231078A (zh) 1997-04-07 2014-12-24 基因技术股份有限公司 抗-血管内皮生长因子的抗体
WO1998048032A2 (fr) 1997-04-21 1998-10-29 Donlar Corporation ACIDE POLY-α-L-ASPARTIQUE, ACIDE-POLY-α-L-GLUTAMIQUE ET COPOLYMERES DE L-ASP ET L-GLU, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION
DE19721700C1 (de) 1997-05-23 1998-11-19 Deutsches Krebsforsch Mutierter OKT3-Antikörper
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US20040191256A1 (en) 1997-06-24 2004-09-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
WO1998058964A1 (fr) 1997-06-24 1998-12-30 Genentech, Inc. Procedes et compositions concernant des glycoproteines galactosylees
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999022764A1 (fr) 1997-10-31 1999-05-14 Genentech, Inc. Compositions renfermant des glycoformes de glycoproteine et methodes afferentes
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
AU2719099A (en) 1998-01-23 1999-08-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Multipurpose antibody derivatives
HUP0100813A3 (en) 1998-02-25 2003-08-28 Lexigen Pharmaceuticals Corp L Enhancing the circulating half-life of antibody-based fusion proteins
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
EP2261229A3 (fr) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Modification par glycosylation d'anticorps aux fins d'amélioration de la cytotoxicité cellulaire dépendant des anticorps
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2341029A1 (fr) 1998-08-17 2000-02-24 Abgenix, Inc. Production de molecules modifiees avec demi-vie serique prolongee
WO2000035956A1 (fr) 1998-12-16 2000-06-22 Kyowa Hakko Kogyo Co., Ltd. Anticorps monoclonal anti-vegf humain
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2003512019A (ja) 1999-01-15 2003-04-02 ジェネンテック・インコーポレーテッド 変化したエフェクター機能を有するポリペプチド変異体
US6676927B1 (en) 1999-01-20 2004-01-13 The Rockefeller University Animal model and methods for its use in the selection of cytotoxic antibodies
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
WO2000053634A1 (fr) 1999-03-10 2000-09-14 Chugai Seiyaku Kabushiki Kaisha Fv monocatenaire induisant l'apoptose
ES2420835T3 (es) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de las moléculas inmunofuncionales
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
ECSP992970A (es) 1999-06-01 2000-01-27 Secuencia del gen relacionado con angiopoyetino scarface 3
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
MXPA02003456A (es) 1999-10-04 2002-10-23 Medicago Inc Metodo para regular la transcripcion de genes foraneos.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2387108A1 (fr) 1999-10-29 2001-06-07 Genentech, Inc. Compositions a base d'anticorps diriges contre l'antigene de cellules souches de la prostate (psca) et procedes d'utilisation associes
WO2001044463A1 (fr) 1999-12-15 2001-06-21 Genentech, Inc. Balayage aveugle, procede combinatoire permettant la representation d'epitopes de proteines fonctionnelles
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
CA2399832C (fr) 2000-02-11 2011-09-20 Stephen D. Gillies Amelioration de la demi-vie circulante de proteines de fusion a base d'anticorps
DK1270595T3 (da) 2000-03-03 2008-11-10 Kyowa Hakko Kogyo Kk Anti-CCR4-antistof og dets fragment
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
JP2003531149A (ja) 2000-04-13 2003-10-21 ザ・ロツクフエラー・ユニバーシテイ 抗体由来の免疫応答の増強
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
US20060034830A1 (en) 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US20060024304A1 (en) 2000-06-28 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
US20060029604A1 (en) 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US20060034828A1 (en) 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
CA2953239A1 (fr) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Cellules produisant des compositions d'anticorps
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101940189A (zh) 2000-11-30 2011-01-12 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2002072608A2 (fr) 2001-03-09 2002-09-19 University Of Chicago Proteines hybrides d'immunoglobulines polymeriques ciblant des recepteurs fc$g(g) a faible affinite
EP2359849A1 (fr) 2001-04-02 2011-08-24 Genentech, Inc. Polytherapie
CA2443903C (fr) 2001-04-13 2018-03-20 Biogen, Inc. Anticorps anti-vla-1
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
GB0118662D0 (en) 2001-07-31 2001-09-19 Univ Southampton Binding agents
EP1423510A4 (fr) 2001-08-03 2005-06-01 Glycart Biotechnology Ag Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
US20030064053A1 (en) 2001-08-31 2003-04-03 Shengjiang Liu Multivalent protein conjugate with multiple ligand-binding domains of receptors
EP1293514B1 (fr) 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimères d'anticorps Fv monocaténaires en tandem
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20060034829A1 (en) 2001-12-27 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform
US20060024292A1 (en) 2001-12-27 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
WO2003073238A2 (fr) 2002-02-27 2003-09-04 California Institute Of Technology Procede informatique de conception d'enzymes pour l'incorporation d'analogues d'acides amines dans des proteines
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20080206242A1 (en) 2002-03-01 2008-08-28 Xencor, Inc. Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20070148171A1 (en) 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US20080152649A1 (en) 2002-03-01 2008-06-26 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
AU2003236019A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
WO2003085119A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
AU2003239966B9 (en) 2002-06-03 2010-08-26 Genentech, Inc. Synthetic antibody phage libraries
JP2006513139A (ja) 2002-07-03 2006-04-20 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 治療薬の全身性送達のための中央部気道投与
US20060062727A1 (en) 2002-07-09 2006-03-23 Philips Heidi S Compositions and methods for the diagnosis and treatment of tumor
BR0313033A (pt) 2002-07-25 2007-07-10 Genentech Inc anticorpos, anticorpos monoclonais, linhagens de células de hibridoma, anticorpos receptores de anti-taci isolados, anticorpos anti -taci, métodos de modulação da atividade biológica
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
DK2345671T3 (en) 2002-09-27 2016-02-15 Xencor Inc Optimized Fc variants and methods for their formation
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PL212899B1 (pl) 2002-12-16 2012-12-31 Genentech Inc Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku
US7608260B2 (en) 2003-01-06 2009-10-27 Medimmune, Llc Stabilized immunoglobulins
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1585767A2 (fr) 2003-01-16 2005-10-19 Genentech, Inc. Banques de phages anticorps synthetiques
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP1639009B1 (fr) 2003-05-30 2013-02-27 Merus B.V. Bibliothèque de fragments fab pour préparer un mélange d'anticorps
KR20120104408A (ko) 2003-05-30 2012-09-20 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
AU2004251145C1 (en) 2003-06-12 2011-04-14 Eli Lilly And Company GLP-1 analog fusion proteins
CN100518817C (zh) * 2003-07-04 2009-07-29 南加州大学 恢复造血功能的治疗剂和组合物及其用途
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (fr) 2003-11-01 2005-05-19 Genentech, Inc. Anticorps anti-vegf
JP2007503206A (ja) 2003-08-22 2007-02-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 変更されたエフェクター機能を有する改良された抗体およびその抗体を産生する方法
AU2004273791A1 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
ES2831379T3 (es) 2003-10-09 2021-06-08 Ambrx Inc Derivados poliméricos para la modificación selectiva de proteínas
CA2545539A1 (fr) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Modification de demi-vies seriques de proteines de fusion fc par mutagenese de positions 250, 314 et/ou 428 de la region constante de la chaine lourde des immunoglobulines
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
HUE031632T2 (en) 2003-11-05 2017-07-28 Roche Glycart Ag Antigen binding molecules with enhanced Fc receptor binding affinity and effector function
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
WO2005063815A2 (fr) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Variants de polypeptides de liaison au recepteur fc$g(g) et procede apparentes
EP2385069A3 (fr) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Variantes de polypeptides Fc se liant au récepteur (FcRn) néonatal, protéines Fc dimèriques et procédés correspondants
EP1701979A2 (fr) 2003-12-03 2006-09-20 Xencor, Inc. Proteines optimisees qui ciblent le recepteur du facteur de croissance epidermique
PL1718677T3 (pl) 2003-12-19 2012-09-28 Genentech Inc Jednowartościowe fragmenty przeciwciała stosowane jako środki lecznicze
WO2005062916A2 (fr) 2003-12-22 2005-07-14 Centocor, Inc. Methodes permettant de generer des molecules multimeres
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
CA2552750C (fr) 2004-01-07 2021-11-09 Chiron Corporation Anticorps monoclonal specifique du m-csf et ses utilisations
WO2005067980A2 (fr) 2004-01-12 2005-07-28 Pointilliste, Inc. Conception d’agents therapeutiques et agents therapeutiques
US7118999B2 (en) 2004-01-16 2006-10-10 International Business Machines Corporation Method and apparatus to increase strain effect in a transistor channel
ES2330860T3 (es) 2004-01-22 2009-12-16 Merck Patent Gmbh Anticuerpos anticancerosos con fijacion del complemento reducida.
EP1718664A4 (fr) 2004-02-02 2008-08-13 Ambrx Inc Polypeptides a faisceau a quatre helices (4hb) humains modifies, et leur utilisation
EP2053062A1 (fr) 2004-03-24 2009-04-29 Xencor, Inc. Variantes d'immunoglobine en dehors de la région Fc
JP5128935B2 (ja) 2004-03-31 2013-01-23 ジェネンテック， インコーポレイテッド ヒト化抗ＴＧＦ−β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005123780A2 (fr) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Modification des affinites de liaison pour le fcrn ou de la demi-vie serique d'anticorps par mutagenese
EP2360186B1 (fr) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anticorps dirigés contre la sélectine P
US20050276806A1 (en) 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of autism
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
EP1786918A4 (fr) 2004-07-17 2009-02-11 Imclone Systems Inc Nouveau anticorps bispecifique tetravalent
EA012464B1 (ru) 2004-08-04 2009-10-30 Эпплайд Молекьюлар Эволюшн, Инк. Антитело против cd20 и его применение
JP2008510466A (ja) 2004-08-19 2008-04-10 ジェネンテック・インコーポレーテッド エフェクター機能が変更しているポリペプチド変異体
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
CN101103045B (zh) 2004-09-24 2015-11-25 安姆根有限公司 修饰的Fc分子
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006047350A2 (fr) 2004-10-21 2006-05-04 Xencor, Inc. Variants d'immunoglobuline igg a fonction effectrice optimisee
EP1810035A4 (fr) 2004-11-10 2010-03-17 Macrogenics Inc Fonction effectrice obtenue par creation par genie biologique de regions d'anticorps fc
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
CN101098890B (zh) 2004-11-12 2012-07-18 赞科股份有限公司 对FcRn的结合被改变的Fc变体
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
CN102746404B (zh) 2004-11-12 2016-01-20 赞科股份有限公司 对FcRn的结合被改变的Fc变体
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
AU2005319382B2 (en) 2004-12-21 2011-04-07 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
US20060275282A1 (en) 2005-01-12 2006-12-07 Xencor, Inc. Antibodies and Fc fusion proteins with altered immunogenicity
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
JP2008531049A (ja) 2005-02-28 2008-08-14 セントカー・インコーポレーテツド ヘテロ二量体タンパク質結合組成物
JP4743388B2 (ja) 2005-03-18 2011-08-10 栗田工業株式会社 フォトレジスト含有排水の処理方法
EP3623473A1 (fr) 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Procédé pour la production de polypeptide au moyen de la régulation d'un ensemble
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
WO2007008943A2 (fr) 2005-07-08 2007-01-18 Xencor, Inc. Proteines optimisees qui ciblent la molecule ep-cam
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
AU2006272804B2 (en) 2005-07-22 2011-02-24 Amgen Inc. Concentrated protein lyophilates, methods, and uses
MY169746A (en) 2005-08-19 2019-05-14 Abbvie Inc Dual variable domain immunoglobulin and uses thereof
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007044887A2 (fr) 2005-10-11 2007-04-19 Transtarget, Inc. Procede de production d'une population homogene d'anticorps bispecifiques tetravalents
EP1957531B1 (fr) 2005-11-07 2016-04-13 Genentech, Inc. Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl
EP1973951A2 (fr) 2005-12-02 2008-10-01 Genentech, Inc. Polypeptides de liaison avec des sequences de diversite limitees
ES2411505T3 (es) 2005-12-15 2013-07-05 Medimmune Limited Combinación del antagonista de la angiopoyetina-2 y del antagonista de VEGF-A, y/o KDR, y/o Flt1 para el tratamiento del cáncer
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
AU2007254005B2 (en) 2006-02-10 2012-11-29 Genentech, Inc. Anti-FGF19 antibodies and methods using same
NZ591252A (en) 2006-03-17 2012-06-29 Biogen Idec Inc Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
ZA200904022B (en) 2006-12-08 2010-08-25 Lexicon Pharmaceuticals Inc Monoclonal antibodies against ANGPTL3
CA2671734A1 (fr) 2006-12-19 2008-06-26 Genentech, Inc. Antagonistes specifiques de vegf pour therapie par adjuvant et neoadjuvant et traitement de tumeurs de premier stade
JP5071942B2 (ja) 2007-01-24 2012-11-14 協和発酵キリン株式会社 エフェクター活性が増強された遺伝子組換え抗体組成物
US10259860B2 (en) 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
KR20100018040A (ko) 2007-06-06 2010-02-16 도만티스 리미티드 프로테아제 내성 폴리펩티드를 선택하는 방법
WO2008149147A2 (fr) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, domaines variables d'anticorps et antagonistes
WO2009006520A1 (fr) 2007-07-03 2009-01-08 Medimmune, Llc Ingénierie de domaine charnière
MX2010001637A (es) 2007-08-17 2010-03-15 Hoffmann La Roche Mediacion de citotoxicidad de celulas que evidencian la expresion superficial de cd9.
KR20100052545A (ko) 2007-08-28 2010-05-19 바이오겐 아이덱 엠에이 인코포레이티드 Ｉｇｆ―１ｒ의 다중 에피토프에 결합하는 조성물
KR20100085067A (ko) 2007-09-28 2010-07-28 추가이 세이야쿠 가부시키가이샤 혈장 중 반응속도가 개선된 항-글리피칸-3 항체
US20090148435A1 (en) 2007-10-30 2009-06-11 Genentech, Inc. Antibody purification by cation exchange chromatography
CN101932608A (zh) 2007-11-30 2010-12-29 葛兰素集团有限公司 抗原结合构建体
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) * 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP4269443A3 (fr) 2007-12-26 2023-12-27 Xencor, Inc. Variants fc avec liaison altérée à fcrn
US8592562B2 (en) 2008-01-07 2013-11-26 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
US8507656B2 (en) 2008-01-28 2013-08-13 Medimmune Limited Stabilized angiopoietin-2 antibodies and uses thereof
KR101666229B1 (ko) 2008-02-08 2016-10-14 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CA2722466A1 (fr) 2008-04-29 2009-11-05 Tariq Ghayur Immunoglobulines a double domaine variable et utilisations
US8293714B2 (en) 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
US20110076723A1 (en) 2008-05-23 2011-03-31 Samsung Electronics Co., Ltd. Antibody-peptide fused synergibody
AU2009259901B2 (en) * 2008-06-20 2016-02-04 Massachusetts Institute Of Technology Immunoglobulins with reduced aggregation
US8349322B2 (en) 2008-06-25 2013-01-08 ESBATech, an Alcon Biomedical Research Unit, LLC Stable and soluble antibodies inhibiting VEGF
US8193321B2 (en) 2008-09-03 2012-06-05 Genentech, Inc. Multispecific antibodies
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
SG10201605250SA (en) 2008-10-14 2016-08-30 Genentech Inc Immunoglobulin variants and uses thereof
PL2376535T3 (pl) 2008-12-09 2017-09-29 F.Hoffmann-La Roche Ag Przeciwciała ANTY-PD-L1 i ich zastosowanie do nasilania działania limfocytów T
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
RU2567639C2 (ru) 2009-06-17 2015-11-10 АббВай Биотерапеутикс Инк., Антитела против vegf и их применения
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
UY32920A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
MX369170B (es) 2010-02-23 2019-10-30 Genentech Inc Combinación concurrente de un anticuerpo anti-vegf con carboplatino y gemcitabina para usarse en el tratamiento de cáncer ovárico.
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
JP2013525484A (ja) 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
US8377337B2 (en) 2010-05-04 2013-02-19 Sabic Innovative Plastics Ip B.V. Method of incorporating an additive into a polyamide-poly(arylene ether) composition, composition prepared thereby, and article comprising the composition
CN102191209A (zh) * 2010-08-26 2011-09-21 苏州大学 VEGF165和Ang-1双基因共表达载体及其应用
DK2691417T3 (en) * 2011-03-29 2018-11-19 Roche Glycart Ag ANTIBODY FC VARIANTS
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CN102250247B (zh) 2011-06-15 2013-06-19 常州亚当生物技术有限公司 一种抗vegf/ang2双特异性抗体及其应用
CN102250248A (zh) 2011-06-15 2011-11-23 常州亚当生物技术有限公司 抗vegf/ang2双特异性抗体及其应用
CN102453577A (zh) 2011-09-21 2012-05-16 李国庆 一种新型煤泥复合燃料及其制备方法
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
AU2013267267B2 (en) 2012-05-31 2017-10-26 Genentech, Inc. Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonists
PL3495387T3 (pl) 2012-07-13 2022-01-10 Roche Glycart Ag Dwuswoiste przeciwciała anty-VEGF/anty-ANG-2 i ich zastosowanie w leczeniu chorób naczyniowych oka

Also Published As

Publication number Publication date
PL2872534T3 (pl) 2018-12-31
CL2017002146A1 (es) 2018-04-13
IL236292A0 (en) 2015-02-26
KR20150023688A (ko) 2015-03-05
CO7151542A2 (es) 2014-12-29
LTPA2023507I1 (fr) 2023-03-10
PL3495387T3 (pl) 2022-01-10
MX2014015518A (es) 2015-06-23
HRP20181595T1 (hr) 2018-12-14
KR101774121B1 (ko) 2017-09-01
UA120029C2 (uk) 2019-09-25
JP2019062905A (ja) 2019-04-25
DK3495387T3 (da) 2021-11-08
MY183712A (en) 2021-03-09
HUE056217T2 (hu) 2022-02-28
JP6154900B2 (ja) 2017-06-28
ZA201408969B (en) 2019-04-24
JP2015527064A (ja) 2015-09-17
EA032192B1 (ru) 2019-04-30
CY1124681T1 (el) 2022-07-22
HK1206365A1 (en) 2016-01-08
AR092027A1 (es) 2015-03-18
FR23C1010I2 (fr) 2024-04-05
SI3495387T1 (sl) 2021-12-31
CN104428315A (zh) 2015-03-18
CA2874554C (fr) 2019-12-03
JP2020062036A (ja) 2020-04-23
AU2013288641B2 (en) 2017-07-06
AU2013288641A1 (en) 2014-12-11
US20230212277A1 (en) 2023-07-06
PE20150361A1 (es) 2015-03-14
US20210095013A1 (en) 2021-04-01
JP6796184B2 (ja) 2020-12-02
TWI506036B (zh) 2015-11-01
NL301218I2 (nl) 2023-04-04
FR23C1010I1 (fr) 2023-04-14
EP3495387B1 (fr) 2021-09-01
ES2896493T3 (es) 2022-02-24
SG11201408538PA (en) 2015-02-27
LT2872534T (lt) 2018-10-25
JP7280859B2 (ja) 2023-05-24
EP2872534B1 (fr) 2018-08-08
NL301218I1 (fr) 2023-02-15
RS57704B1 (sr) 2018-12-31
NZ702201A (en) 2018-01-26
TW201406782A (zh) 2014-02-16
MA37794A1 (fr) 2016-03-31
CA2874554A1 (fr) 2014-01-16
SI2872534T1 (sl) 2018-11-30
WO2014009465A1 (fr) 2014-01-16
EP3495387A1 (fr) 2019-06-12
PT2872534T (pt) 2018-10-26
LT3495387T (lt) 2021-11-25
MX361337B (es) 2018-12-04
CL2015000061A1 (es) 2015-05-08
US20170260265A1 (en) 2017-09-14
US10683345B2 (en) 2020-06-16
US9695233B2 (en) 2017-07-04
EP2872534A1 (fr) 2015-05-20
CR20140542A (es) 2015-02-12
AR124240A2 (es) 2023-03-01
HRP20211641T1 (hr) 2022-02-04
HUS2300008I1 (hu) 2023-02-28
NO2023009I1 (no) 2023-02-14
IN2014DN11157A (fr) 2015-10-02
DK2872534T3 (en) 2018-10-22
RS62509B1 (sr) 2021-11-30
PH12014502713A1 (en) 2015-02-02
ES2690312T3 (es) 2018-11-20
PH12014502713B1 (en) 2015-02-02
JP6640319B2 (ja) 2020-02-05
IL236292B (en) 2020-06-30
CN104428315B (zh) 2017-09-29
JP2021036888A (ja) 2021-03-11
JP2017140038A (ja) 2017-08-17
US20140017244A1 (en) 2014-01-16
EA201500132A1 (ru) 2015-08-31
JP6462750B2 (ja) 2019-01-30
FIC20230011I1 (fi) 2023-02-13

Similar Documents

Publication Publication Date Title
MA37794B1 (fr) Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le cadre du traitement de pathologies vasculaires oculaires
MA34172B1 (fr) Anticorps bispécifiques, bivalents anti-vegf/anti-ang-2
CY1119596T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
IN2014KN02933A (fr)
MA35458B1 (fr) Variants du facteur de croissance des fibroblastes 21
TN2015000174A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201591166A1 (ru) Ингибиторы аутотаксина
EP3147285A3 (fr) Composés de purinone en tant qu'inhibiteurs de kinase
MA32876B1 (fr) Anticorps dirigés contre l'angiopoïétine 2 humaine
UA109650C2 (xx) Біс-арилзв'язані арилтриазолони та їх застосування
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
MA35130B1 (fr) Composition comprenant de l'aflibercept, de l'acide folinique, du 5-fluoro-uracile (5-fu) et de l'irinocetan (folfiri)
TR201907261T4 (tr) DKK-1 antikorları.
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
MA33349B1 (fr) Compositions pharmaceutiques solides et procedes pour leur production
EA201390310A1 (ru) Фармацевтические композиции, содержащие рифаксимин, способы их получения и способ лечения кишечного заболевания
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
MY166288A (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
MA38190A2 (fr) Inhibiteurs d'autotaxine
MX2022008842A (es) Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial.
EA201300128A1 (ru) Комбинированная фармацевтическая композиция и способы лечения заболеваний или состояний, связанных с нарушением функции сердечно-сосудистой системы